Acute Flaccid Myelitis
Also known as: AFM
Methodology & AI Transparency ⓘ
Acute Flaccid Myelitis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is acute flaccid myelitis (AFM)? Acute flaccid myelitis (AFM) is a neurologic disease .
- 2 Real-world patient consensus: Clinical coding for Acute Flaccid Myelitis uses ICD-10 J06.8 across Infections & Antivirals specialty care.
- 3 Typical cash cost range: Differential triage of Acute Flaccid Myelitis (J06.8) utilizes antimicrobial stewardship (narrow-spectrum in Acute Flaccid Myelitis (J06.8: pathogen-directed duration) or).
- 4 Top reported side effects / signs: Follow-up benchmark in Acute Flaccid Myelitis: maintaining C-Reactive Protein / in Acute Flaccid Myelitis (J06.8: Procalcitonin) within Resolution to baseline (J06.8).
Ask our AI Specialists anything about Acute Flaccid Myelitis
What Is Acute Flaccid Myelitis?
What is acute flaccid myelitis (AFM)? Acute flaccid myelitis (AFM) is a neurologic disease . It is rare, but serious. It affects an area of the spinal cord called gray matter. This can cause the muscles and reflexes in the body to become weak. Because of these symptoms, some people call AFM a "polio-like" illness. But it is different from polio . AFM is not caused by polioviruses. What causes acute flaccid myelitis (AFM)? AFM can be caused by several different viruses. Researchers think that enteroviruses have been causing the recent increases in the number of children with AFM.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Acute Flaccid Myelitis (J06.8) features or latent viral in Acute Flaccid Myelitis (J06.8: reactivation within sensory). therapeutic stabilization in infections & antivirals is verified against Targeted PCR / in Acute Flaccid Myelitis (J06.8: Culture & Sensitivity).
Common Symptoms & Clinical Signs
- • Arm or leg weakness
- • A loss of muscle tone and reflexes
- • Presentation of Acute Flaccid Myelitis (J06.8): regional lymph node in Acute Flaccid Myelitis (J06.8: tenderness or acute)
- • Secondary Acute Flaccid Myelitis clinical sign: acute fever, chills, in Acute Flaccid Myelitis (J06.8: malaise, and myalgias)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Acute Flaccid Myelitis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | J06.8 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: C-Reactive Protein / in Acute Flaccid Myelitis (J06.8: Procalcitonin) | Resolution to baseline (J06.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Targeted PCR / in Acute Flaccid Myelitis (J06.8: Culture & Sensitivity) | Pathogen clearance / negative test (J06.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Acute Flaccid Myelitis (J06.8: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (J06.8) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Acute Flaccid Myelitis
Treatment selection for Acute Flaccid Myelitis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Acute Flaccid Myelitis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Intermittent or Continuous kidney-Replacement Therapy in Acute Kidney New England Journal of Medicine, Volume 395, Issue 17 , Page 1677-1690, October 29, 2026. New England Journal of Medicine • 2026-10-14 • Peer-Reviewed Journal (Clinical Trials) | Multi-cohort | 97/100 | PMID NEJM-62256824 ↗ |
| New Insights on Baseline data, initial course, and management: losartan versus captopril: What a 5,477-Participant Study Found A total of 5,477 patients with heart failure during the acute phase or with a new Q-wave anterior infarction or reinfarction were recruited. The American journal of cardiology • 2001-03-15 • Randomized Controlled Trial | N = 5,477 | 96/100 | PMID 11249900 ↗ |
| New Insights on Reductions in acute medication use and healthcare resource utilization in: What a 1,113-Participant Study Found Treatment with galcanezumab resulted in significant reductions in headache medication overuse and migraine headache days requiring acute medication use, with notable reductions in migraine-specific HCRU. Journal of medical economics • 2022-01-15 • Phase III Randomized Trial | N = 1,113 | 96/100 | PMID 35971655 ↗ |
| New Insights on Evaluating the real-world benefits and safety of SpikoGen®, an: What a 4,219-Participant Study Found 12 657 and 4219 participants were randomized to the SpikoGen® and placebo group and followed for a median of 55 days (interquartile range, 48-60 days) and 51 days. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases • 2023-02-15 • Phase III Randomized Trial | N = 4,219 | 96/100 | PMID 36096430 ↗ |
| New Insights on Comparative Efficacy of Statins for Prevention of Contrast-Induced Acute Kidney: What a 6,385-Participant Study Found Results showed that statin loading before contrast administration was associated with a significantly reduced risk of CI-AKI in patients with CKD undergoing cardiac catheterization (odds ratio: 0.46; P < .05). Angiology • 2019-04-15 • Meta-Analysis | N = 6,385 | 94/100 | PMID 30261736 ↗ |
Acute Flaccid Myelitis Patient Community & “People Like Me” Threads
Filter Acute Flaccid Myelitis community threads and patient logs by age, biological sex, dosage, and treatment duration.
Tracking C-Reactive Protein / in Acute Flaccid Myelitis (J06.8: Procalcitonin) every 12 weeks for Acute Flaccid Myelitis: what lab cadence worked best?
FDA/PubMed Clinical Context Note: Clinical guidelines across Bacterial, Viral & Fungal Infections (Acute Flaccid Myelitis, ICD-10-CM J06.8) generally pair 8-to-12-week repeat biomarker verification (C-Reactive Protein / in Acute Flaccid Myelitis (J06.8: Procalcitonin): Resolution to baseline (J06.8)) with symptom review so steady-state physiological response is captured accurately.
After being diagnosed with Acute Flaccid Myelitis (ICD-10 J06.8), my clinician and I set a goal around C-Reactive Protein / in Acute Flaccid Myelitis (J06.8: Procalcitonin) (Resolution to baseline (J06.8)) before escalating medication doses. For others managing infections & antivirals markers, did quarterly bloodwork catch changes early enough without over-testing?
12-week intervals worked really well for tracking C-Reactive Protein / in Acute Flaccid Myelitis (J06.8: Procalcitonin). Using the same morning fasting draw window each quarter eliminated day-to-day noise so my doctor could adjust cleanly.
Ordering C-Reactive Protein / in Acute Flaccid Myelitis (J06.8: Procalcitonin) alongside standard preventive labs prior to my follow-up visit saved an extra co-pay and kept our appointment focused on actual trend lines.